# Kvika Asset Management

> Kvika Asset Management is a VC fund in Reykjavík backing Medical and Health Care. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Reykjavík, Iceland
- Total investments: 2
- Last investment: Aug 2024
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/kvika-assetmanagement/
- Website: https://www.kvikaeignastyring.is/

Kvika Asset Management is a VC fund in Reykjavík focused on Medical and Health Care. Kvika Asset Management manages a broad range of funds including equity funds, bond funds and mixed funds.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 50% |
| Health Care | 1 | 50% |
| Biotechnology | 1 | 50% |
| Pharmaceutical | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 50% |
| Series A | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| PLAIO | PLAIO is a web-based SaaS platform intended to help generic pharmaceutical companies to digitize their demand, manufacturing, and purchase planning.PLAIO offers features like visual and capacity planning, advanced constraint/overhead calculations. | $4.7M | Seed | Aug 14, 2024 |  |
| EpiEndo Pharmaceuticals | EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to inflammatory disorders that focuses on the enhancement of epithelial barrier integrity as a causal pathophysiological factor underlying the etiology of a number of major diseases. Epithelial cells are a key component of the barrier that makes up human skin and lungtissue, as well as the intestinal tract and genitalia. Compromised integrity of this barrier is implicated in the progression and non-resolution of inflammation.EpiEndo is developing a proprietary portfolio of orally available macrolide drug candidates with promise as first-in-class disease-modifying therapeutics, to address the huge global burden of chronic respiratory diseases and other significant unmet medical needs.EpiEndo’s lead drug candidate, EP395, aims to be the first on-market oral, disease modifying, non-antibiotic, barrier strengthening and anti-inflammatory macrolide for COPD and other inflammatory airway diseases. | $23.4M | Series A | Aug 18, 2021 |  |

2 of 2 investments shown.

## Co-investors
- [ABC Ventures](https://shizune.co/investors/profile/abc-ventures) — VC Fund, 1 deal together
- [Dr. Agon](https://shizune.co/investors/profile/dr-agon) — VC Fund, 1 deal together
- [European Innovation Council](https://shizune.co/investors/profile/european-innovation-council) — VC Fund, 1 deal together
- [Flerie Invest](https://shizune.co/investors/profile/flerie-invest) — VC Fund, 1 deal together
- [Frumtak Ventures](https://shizune.co/investors/profile/frumtak) — VC Fund, 1 deal together
- [Idunn venture fund](https://shizune.co/investors/profile/idunn-venture-fund) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [New Business Venture Fund](https://shizune.co/investors/profile/new-business-venture-fund) — VC Fund
- [Frumtak Ventures](https://shizune.co/investors/profile/frumtak) — VC Fund
- [Brunnur Ventures](https://shizune.co/investors/profile/venture-capital-fund-brunnur) — VC Fund

## Featured in investor lists
- [All VC Funds in Iceland](https://shizune.co/investors/vc-funds-iceland)
- [All Investors in Iceland](https://shizune.co/investors/investors-iceland)
- [Medical VC Funds in Iceland](https://shizune.co/investors/medical-vc-funds-iceland)
- [Biotechnology Investors in Iceland](https://shizune.co/investors/biotechnology-investors-iceland)
- [Biotech Investors in Iceland](https://shizune.co/investors/biotech-investors-iceland)
- [Biotech VC Funds in Iceland](https://shizune.co/investors/biotech-vc-funds-iceland)

## FAQ

### What does Kvika Asset Management invest in?

Kvika Asset Management invests primarily in Medical, Health Care and Biotechnology startups, most often at Seed and Series A stage. Most of the 2 investments tracked by Shizune back companies in Iceland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Kvika Asset Management last invest?

The most recent investment recorded for Kvika Asset Management closed in Aug 2024. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co